Common people Help me Out-- Very tempted to but GOOSE here! Canada Goose Holdings Inc. (GOOS) NYSE - Nasdaq Real Time Price. Currency in 39.77-1.51(-3.66%) As of 10:59AM EST.
XpresSpa Group and Ginkgo Bioworks Collaboration with the Centers for Disease Control and Prevention (CDC) COVID-19 Biosurveillance Program Expands to Include Detection of the New Omicron Variant XpresSpa Group, Inc. Tue, November 30, 2021, 9:00 AM In this article: The current COVID-19 variant surveillance program is offered at John F. Kennedy International Airport, Newark-Liberty International Airport, San Francisco International Airport, and is now expanding to Hartsfield-Jackson Atlanta International Airport NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced through a joint effort with the Centers for Disease Control and Prevention (CDC) and Ginkgo Bioworks (NYSE: DNA), the expansion of its current COVID-19 variant surveillance program to detect the new Omicron variant through its XpresCheck subsidiary. On Saturday, November 27, the White House announced new travel restrictions applicable to eight African countries in response to a new COVID-19 variant of concern, designated as “Omicron” by the World Health Organization. - ADVERTISEMENT - “Information about the Omicron variant is rapidly evolving,” said Dr. Martin Cetron, the Director for the Division of Global Migration and Quarantine (DGMQ) at the U.S. Centers for Disease Control and Prevention (CDC). “We are actively working to scale up this collaborative post-arrival airport-based surveillance testing program to monitor for this new variant in arriving travelers.” On Sunday, November 28, XpresCheck expanded its COVID-19 biosurveillance program to test passengers entering the United States from Southern Africa, including passengers making connections through Europe. The initial COVID-19 biosurveillance program launched in September and provided testing for travelers arriving from India at three key United States airports, John F. Kennedy International Airport, Newark-Liberty International Airport, and San Francisco International Airport, and is expanding to include Hartsfield-Jackson Atlanta International Airport. The CDC’s program, conducted in collaboration with XpresCheck and Ginkgo Bioworks, offers two types of free testing options. The first is a PCR test done on a pooled sample collected at the airport on arrival. A pooled test means several passengers’ samples are combined together and tested as a group. This approach enables efficient large-scale testing of many passengers entering the country. The second option is an at-home specimen collection kit that passengers can take with them and mail back a sample collected three to five days after arrival into the United States for individualized PCR testing. The CDC strongly encourages all international travelers to get tested three to five days after arrival in the United States. Through this program, results are provided to passengers and public health authorities to help interrupt the chain of transmission in US communities, and detect variants of concern entering the United States. Ginkgo Bioworks’ biosecurity and public health effort, Concentric by Ginkgo, will manage the testing program, which includes genetic sequencing of positive tests to detect presence of the new variant of concern or other SARS-CoV-2 variants. The CDC uses these results for ongoing surveillance purposes, in order to inform public health decision-making. “Over the past three months, we’ve been accumulating real-world experience in conducting an airport-based COVID-19 surveillance of international arriving passengers, while refining and streamlining our testing processes to maximize program results,” said Doug Satzman, XpresSpa Group CEO. “Now that we’ve got the network built and running smoothly, we believe we can rapidly pivot to adapt to any new variants of concern, including the latest Omicron variant.” “We stand ready to provide the biosecurity tools and expertise needed to give our public health leaders the weather map they need at this point in the pandemic,” said Matthew McKnight, Ginkgo Bioworks’ Chief Commercial Officer. “This collaboration with the incredible teams at XpresCheck and the CDC will provide critical information for passengers, for communities, and for national pandemic response.” About XpresSpa Group, Inc. XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company operating three distinct brands: Treat™, XpresCheck™, and XpresSpa™. Treat is a travel health and wellness brand that will be providing on-demand access to healthcare through technology and personalized services. XpresCheck is a leading on-site airport provider of COVID-19 screening and testing with 14 locations in 12 domestic airports. XpresSpa is a leading airport retailer of spa services and related health and wellness products, with 43 locations in 21 airports globally. /////// This stock actually needs to raise funds top expand and the stk would take off-- I don't see why this isn't going to work. 14 locations become 28 and profits double....//
Lol... great minds. I just bought 500 at $28. If it starts up, it'll move fast. Huge short interest. They'll start covering. They made a nice score.
I LIKE GOOSE WHO'S WITH ME-! Canada Goose Holdings Inc. GOOS: This designer, manufacturer, and seller of performance luxury apparel for men, women, youth, children, and babies has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 21.8% over the last 60 days. Canada Goose Holdings Inc. Price and Consensus Canada Goose Holdings Inc. Price and Consensus Canada Goose Holdings Inc. price-consensus-chart | Canada Goose Holdings Inc. Quote Canada Goose's shares gained 8% over the last one month. The company possesses a Momentum Score of B. Canada Goose Holdings Inc. Price Canada Goose Holdings Inc. Price Canada Goose Holdings Inc. price | Canada Goose Holdings Inc. Quote
Interesting chart, that's for sure. How's the doggie? Did you just take him to the vet? Hey btw, I picked up 200 of our ACC a little while ago. $50.75. I think GOOS will be ok. It won't rocket overnight but its safe.
You're on a roll Van keep going. Confluent, Inc. (CFLT)-- just watching for now-- NasdaqGS - NasdaqGS Real Time Price. Currency in USD 75.80+5.24 (+7.43%) As of 11:34AM EST.
Please nominate a worst stock of the year. To be clear a worst stock is not just a bad performing stock it is in essence a good idea not delivered upon by management and or completely disregarded by the market.
Well, one stock comes to mind, and that's SNAP. One of the reasons they're down so much is because there's about 2 dozen law firms doing their class action thing based on the CEO's public remarks back in February. He said Apple's IOS changes wouldn't have a material effect on their revenue. We see how that worked out. Others: DKNG, CRSR SJM ---- my granny stock that owns a 100 of America's most well known brands and can't break $140 to save its life. The CEO is a Smucker, and his dad is the Chairman. If they ever announce the family is stepping aside and bring in a WS shark to run that place, it'll jump 50% overnight. That's why I hold it. And speaking of families... one more, and somewhere in our old thread when it was north of $50 I wrote it's a $17 stock at best... and that's what it just took out yesterday. GRWG